Shutter-Speed Model DCE-MRI for Assessment of Response to Cancer Therapy

用于评估癌症治疗反应的快门速度模型 DCE-MRI

• 批准号: 8327116
• 负责人: WEI HUANG
• 金额: $ 57.67万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8327116
• 关键词: Accounting; Anatomy; Area; Biological Markers; Blood Vessels; Clinical Data; Clinical Management; Clinical Oncology; Clinical Research; Clinical Trials; Communities; Computer software; Data; Diffusion Magnetic Resonance Imaging; Discrimination; Disease; Drug Kinetics; Enrollment; Equilibrium; Evaluation; Guidelines; Image; Image Analysis; Imagery; Individual; Kinetics; Magnetic Resonance Imaging; Malignant Neoplasms; Measurement; Measures; Methods; Modeling; Monitor; Output; Pathology; Patients; Phase; Population; Principal Investigator; Process; Publishing; Recruitment Activity; Reproducibility; Research; Residual Cancers; Resolution; Scheme; Scientist; Services; Software Tools; Speed; System; Therapeutic; Time; Translations; Uncertainty; Water; anticancer research; bioimaging; caGrid; cancer Biomedical Informatics Grid; cancer therapy; clinical decision-making; comparative efficacy; computerized data processing; data acquisition; drug development; efficacy evaluation; image archival system; imaging modality; improved; malignant breast neoplasm; novel; open source; pharmacokinetic model; response; sarcoma; simulation; soft tissue; software development; tool; tumor

DESCRIPTION (provided by applicant): In clinical oncology and drug development there is genuine need for sensitive and reproducible quantitative imaging methods for early prediction of therapy response and accurate assessment of post-therapy residual cancer. Such methods have the potential to spare non-responding patients from ineffective and/or toxic treatments, improve clinical management, and accelerate efficacy evaluation of novel therapies. Dynamic- Contrast-Enhanced (DOE) MRI can provide an excellent measure of therapy-induced tumor vascular changes. The Standard-Model (SM) for pharmacokinetic DCE-MRl analysis incorrectly assumes effectively infinitely fast equilibrium inter-compartmental water exchange kinetics and, as a result, often underestimates the pharmacokinetic parameters Ktrans and Ve. The Shutter-Speed Model (SSM) accounts for finite water exchange kinetics effects and corrects the imaging biomarker underestimations. It has proven more sensitive to vascular changes than the SM. In addition, SSM DCE-MRl allows quantification of novel imaging biomarkers, such as ?Ktrans(= Ktrans (SSM) - Ktrans (SM)] - a measure of precisely the water exchange (shutter-speed) effect on Ktrans estimation. ?Ktransis not only a more sensitive biomarker for therapeutic response, but also less prone to other systematic errors often observed in DCE-MRl quantification. In Specific Aim 1, the Shutter-Speed Model will be applied to phase l/ll clinical trials in two disease areas (breast cancer and soft tissue sarcoma), SSM DCE-MRl will be compared/combined with SM DCE-MRl, diffusion-weighted MRI and tumor size measurement for assessment of therapy response. In Aim 2, the effects of data acquisition and processing schemes on DCE-MRl biomarker values will be investigated within the context of therapeutic monitoring. In Aims 1 and 2, pathology results will be used as endpoints for correlation with imaging results and statistical analyses. In Aim 3, caBIG-compliant software tools will be developed that utilize a single and/or a set of imaging biomarkers to aid clinical research.

描述（由申请人提供）：在临床肿瘤学和药物开发中，确实需要灵敏且可重复的定量成像方法，用于早期预测治疗反应和准确评估治疗后残留癌症。这些方法有可能使无反应的患者免受无效和/或有毒的治疗，改善临床管理，并加速新疗法的疗效评估。动态对比增强 (DOE) MRI 可以很好地测量治疗引起的肿瘤血管变化。用于药代动力学DCE-MR1分析的标准模型(SM)错误地假设有效无限快速平衡室间水交换动力学，并且因此常常低估药代动力学参数Ktrans和Ve。快门速度模型 (SSM) 考虑了有限的水交换动力学效应，并纠正了成像生物标志物的低估。事实证明，它比 SM 对血管变化更敏感。此外，SSM DCE-MR1 允许量化新颖的成像生物标志物，例如 ΔKtrans(= Ktrans (SSM) - Ktrans (SM)] - 精确测量水交换（快门速度）对 Ktrans 估计的影响。不仅是治疗反应更敏感的生物标志物，而且不易出现在 DCE-MR1 定量中经常观察到的其他系统误差。在具体目标 1 中，快门速度模型将应用于相位。在两个疾病领域（乳腺癌和软组织肉瘤）的1/11临床试验中，SSM DCE-MR1将与SM DCE-MR1、扩散加权MRI和肿瘤大小测量进行比较/组合，以评估目标2中的治疗反应。在目标 1 和 2 中，将在治疗监测的背景下研究数据采集和处理方案对 DCE-MR1 生物标志物值的影响，病理学结果将用作与成像相关的终点。在目标 3 中，将开发符合 caBIG 的软件工具，利用单个和/或一组成像生物标志物来辅助临床研究。